Osthole

Drug Profile

Osthole

Alternative Names: Osthol

Latest Information Update: 02 Nov 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator
  • Developer Kyoto University; Nippon Chemiphar
  • Class Anti-inflammatories; Antiasthmatics; Coumarins; Eye disorder therapies; Small molecules
  • Mechanism of Action Calcium channel antagonists; Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Liver disorders; Ocular inflammation

Most Recent Events

  • 02 Apr 2001 Preclinical development for Liver disorders prevention in Japan (Unknown route)
  • 02 Apr 2001 A preclinical study has been added to the Liver Disorders pharmacodynamics section
  • 26 Jun 1998 No-Development-Reported for Asthma in Taiwan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top